Despite both being keratinocyte-derived skin cancers, basal cell carcinoma (BCC) responds much less robustly to immunotherapy than cutaneous squamous cell carcinoma (CSCC). The pathologic complete response rate to perioperative PD-1 inhibition in BCC is only 23%, less than half the 51% seen in CSCC, highlighting their distinct immunobiology.

For high-risk patients, oral acitretin has the strongest evidence for preventing skin cancers, with 30-50% efficacy. This is significantly higher than the debatable 20% efficacy of nicotinamide (Vitamin B3). Topical treatments like retinoids are considered ineffective for this purpose.

Among solid organ transplant patients, who are already at high risk for skin cancer, heart transplant recipients are at the greatest risk. This is specifically due to the type and duration of immunosuppressive drugs required to prevent organ rejection, highlighting a critical sub-population for dermatologic surveillance.

A positive genetic test does not automatically mandate the most aggressive surgery. For older patients, such as a 70-year-old with a new breast cancer and BRCA mutation, the clinical context—life expectancy, overall health—is paramount. A "knee-jerk" bilateral mastectomy may be overtreatment in such cases.

Your family's medical history offers clues to which cellular aging processes are most vulnerable. A history of diabetes points to glycation issues (Tenet 7), while various cancers suggest weak DNA repair (Tenet 4), enabling a personalized anti-aging focus.

Nonmelanoma skin cancers' sensitivity to checkpoint inhibitors is due to high tumor mutational burden (TMB) caused by chronic UV light damage. This high TMB creates numerous neoantigens, which the immune system can effectively target once immunotherapy reverses immune suppression.

Experts argue that radiation therapy is often wrongly perceived as a salvage or adjuvant option. For many patients with early-stage basal or squamous cell carcinomas, it offers local control rates over 95%, comparable to surgery, and should be presented as a primary alternative, especially when cosmetic outcomes are a priority.

Unlike in lung cancer, PD-L1 expression levels do not guide treatment for nonmelanoma skin cancers. Patients with low or even negative PD-L1 levels still show significant response to anti-PD-1 therapy, making the test an unhelpful discriminator for treatment decisions.

Experts advise against using gene expression profiling to escalate care for CSCC (e.g., deciding to add systemic therapy). Its primary utility is in de-escalation: a low-risk profile can provide an additional data point to support a decision for observation in a borderline high-risk case, helping to avoid overtreatment.